Investigation of intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA of chronic hepatitis B patients whom neither serum hepatitis B e antigen nor HBV DNA has been detected for more than 6 months during oral antiviral therapy

Investigation of intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA of chronic hepatitis B patients whom neither serum hepatitis B e antigen nor HBV DNA has been detected for more than 6 months during oral antiviral therapy - Investigation of intrahepatic HBV ccc DNA of chronic hepatitis B patients during oral antiviral therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004982

Enrollment

Registered

2011-01-31

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronically HBV infected patients in whom neither serum hepatitis Be antigen nor HBV DNA has been detected for more than 6 month during oral antiviral therapy (lamivudine, entecavir, adefovir or both of thme).

Exclusion criteria

Exclusion criteria: liver cirrhosis

Design outcomes

Primary

Measure	Time frame
Involvement of intrahepatic HBV ccc DNA eradication or remaining with viral reactivation after cessation of antiviral dosing	—

Countries

Japan

Contacts

Public ContactYoshinobu Saito

Osaka Prefectual General Medical Center Department of Gastroenterology and Hepatology

saito_yoshinobu@hotmail.com06-6692-1201

Outcome results